Read This First
This page is not built on clinical evidence. Cost and access are commercial facts, not scientific findings.
TB-500 has no approved product, no list price, and no regulated market. Prices differ widely between channels, and none of that spread reflects a verified difference in what is inside the vial. What follows is what determines the price, which stays true when the numbers move.
Why There Is No Price
What a Price Normally Sits On
For an approved medicine, a price sits on top of a known quantity of a known substance, manufactured to a validated standard, for a stated indication. The number means something because everything underneath it is fixed.
For TB-500, none of that holds. It is not approved for human use anywhere. There is no manufacturing standard applying across sellers, no verified label quantity, and no approved indication.3
What Drives the Differences
| Cost component | Present in | What it buys |
|---|---|---|
| Consultation and clinician time | Clinics, some telehealth | A history, a record, and someone accountable |
| Prescriber liability and insurance | Clinics, telehealth | Recourse if something goes wrong |
| Premises and staff | Clinics | Overhead, not product |
| Marketing and affiliate commission | All channels, often invisible | Nothing for the buyer |
| The peptide itself | All channels | Frequently the smallest line in the total |
Most of the gap between a clinic price and a research vendor price is service and accountability. Almost none of it is verified product quality, because no channel offers that.
The Comparison Trap Specific to TB-500
Why Per-Vial Pricing Misleads Here
TB-500 and BPC-157 are used in different orders of magnitude. Reported TB-500 protocols run in milligrams per administration, while BPC-157 protocols run in micrograms. The observed patterns are documented in the ONPEPS dosage guide.
The consequence for cost is straightforward. A comparable period of use consumes far more TB-500 material, so two vials priced similarly do not represent similar amounts of use. Comparing headline vial prices between the two compounds tells you almost nothing about what a period of use will cost.
The useful comparison is cost per milligram, then cost across the intended duration.
Are Blended Vials Better Value?
A combined BPC-157 and TB-500 vial is usually cheaper than buying both separately. Three things come with that saving.
The ratio is fixed by the seller and cannot be adjusted afterwards. Neither component can be stopped independently if a problem develops. And two unverified substances share one container and usually one certificate, which doubles the identity question covered on the sourcing page.
There is also an evidence point worth knowing before paying for a blend. The only controlled comparison that exists, a 2026 rat study of Achilles tendon repair testing each agent alone and combined, reported that combined treatment did not confer additional benefits over either agent alone.2 That is an exploratory animal study, not a verdict. It is also the only controlled evidence on the question, and it does not support paying for both.
Is a Larger Vial Better Value?
Cost per milligram usually falls with vial size. Against that: once reconstituted, a vial has a limited usable life, and no product-specific stability data exist for TB-500 to define what that life is.
Buying more of an unverified product also concentrates the risk. If the batch is wrong, a larger vial means more of the wrong thing.
Insurance and Health Accounts
Does Insurance Cover It?
No. Insurers cover approved treatments for approved indications. TB-500 is not approved for human use anywhere, so there is no billing code, no formulary position, and no coverage decision to appeal.
This is not a difficult prior authorization. There is no pathway to argue into.
HSA and FSA Funds
Tax-advantaged health accounts are governed by rules on qualified medical expenses, which generally require a legitimate medical purpose and often documentation from a provider. An unapproved substance sits awkwardly against those requirements.
Rules vary by plan and jurisdiction, and the account holder carries the consequences if an expense is disallowed. That is a question for the plan administrator.
Clinics
Medical Care or Sales Channel?
Both models exist, and the sign on the door does not tell you which one you are in. The tell is whether the clinic is capable of concluding that you should not take the product. A clinic whose revenue depends on you leaving with a vial has an obvious difficulty reaching that conclusion.
What to Ask Before Paying
What human evidence supports this for my condition? A straight answer acknowledges that no human trial of TB-500 has reported results, and that the only registered trial is recruiting for cardiovascular biomarkers rather than injury recovery.3
Is this TB-500 or thymosin beta-4? They are different molecules with different research records.1
Can I see a certificate of analysis matched to the batch I will receive, and does it include identity testing or only purity?
Free base or acetate? The FDA treats them as distinct substances.4
What is the legal basis on which you are supplying this?
Under what circumstances would you tell a patient not to use this?
Does anyone here receive commission on product sales?
If I compete in any tested sport, what are you telling me? It is prohibited under WADA section S2 and named explicitly.5
Questions two, six and seven are the informative ones. A clinic that cannot distinguish TB-500 from thymosin beta-4 is not equipped to advise on either.
The Spending Decision
What the Money Buys
The evidence base for TB-500 is 16 PubMed records, most of them reviews mentioning it alongside other peptides or analytical chemistry developing detection methods. No human trial has reported results, and the first one registered is still recruiting.1,3
A 2024 study stated that the biological effects of TB-500 have not been documented, and concluded that the wound-healing activity reported in the literature may be due to a metabolite rather than the parent compound.1
That last point has a direct financial reading. The study raises the possibility without settling it, but if the activity does belong to a breakdown product rather than the compound in the vial, then the milligram figure on a label is not a measure of the active agent delivered, and no published work lets anyone convert one into the other.
Spending here is a purchase of possibility, not of expected outcome. That does not make it irrational, but it makes it a bet rather than a treatment, and anyone spending should know which one they are doing.
Should the Money Go Elsewhere?
Structured rehabilitation has an evidence base for musculoskeletal injury that TB-500 does not. The observational patterns ONPEPS has documented also associate the strongest reported responses with maintained rehabilitation rather than with the compound alone.
That association cannot establish causation. What it suggests is that a budget spent on the peptide while skipping rehab is being spent on the component with less support behind it.
Related ONPEPS Coverage
Sources
Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. Free article. pubmed.ncbi.nlm.nih.gov/38382158
Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. Free article. pubmed.ncbi.nlm.nih.gov/42542926
Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. Paywalled. pubmed.ncbi.nlm.nih.gov/41476424
US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. fda.gov
United States Anti-Doping Agency. 2018 Prohibited List: Summary of Major Changes. Archived advisory; see reference for current-year status. Accessed 12 August 2026. usada.org
Not Medical or Financial Advice
TB-500 is not approved for human use in any jurisdiction and is prohibited in sport. Treatment decisions belong with a qualified healthcare provider.
Sources verified 12 August 2026. Regulatory status is unsettled following the July 2026 advisory recommendation and should be re-checked against FDA docket FDA-2025-N-6895.